This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for UnitedHealth (UNH) This Earnings Season?
by Zacks Equity Research
UnitedHealth's (UNH) earnings results are likely to reflect solid contribution from its segments, namely Healthcare and Optum, partly offset by higher claim costs.
What's in Store for Intuitive Surgical's (ISRG) Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.
The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics
Testing Space in Focus Again Thanks to New Wave of Coronavirus
by Urmimala Biswas
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
Abbott (ABT) to Expand in Booming TBI Space on New Approval
by Zacks Equity Research
If positive, Abbott's (ABT) TBI blood test result complements CT scans to help evaluate whether a suspected patient has a TBI.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $111.30, moving +0.97% from the previous trading session.
Why Abbott (ABT) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $109.49 in the latest trading session, marking a +0.97% move from the prior day.
5 Soaring MedTech Stocks to Buy for More Growth in 2021
by Urmimala Biswas
We have selected five MedTech growth stocks with further rooms for improvement in 2021.
3 Soaring MedTech Stocks That Might Lose Ground in 2021
by Trina Mukherjee
Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $108.09, marking a -0.81% move from the previous day.
4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2021
by Zacks Equity Research
Four large-cap MedTech stocks are currently flourishing on the back of several positive developments
Abbott (ABT) Broadens Pediatric Client Base With New Labeling
by Zacks Equity Research
Abbott's (ABT) HeartMate 3 LVAD or heart pump is an implantable device that pumps blood through the body in people whose hearts are too weak to do so naturally.
5 MedTech Stocks That Have Outperformed the Industry in 2020
by Debanjana Dey
Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.
Abbott (ABT) Gains CE Mark for Quantitative Serology Testing
by Zacks Equity Research
The test is set to be used on Abbott's (ABT) ARCHITECT and Alinity i platforms.
Abbott (ABT) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $106.79 in the latest trading session, marking a -0.23% move from the prior day.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.
Abbott (ABT) Launches Immunity Boosting Hydration Solution
by Zacks Equity Research
Abbott's (ABT) latest hydration solution with specifically chosen nutrients along with optimal balance of electrolytes and glucose is expected to boost immunity.
3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021
by Sriparna Ghosal
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
Abbott (ABT) Stock Moves -0.45%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $106.32, moving -0.45% from the previous trading session.
4 Top-Ranked MedTech Stocks to Bet on Heading Into 2021
by Trina Mukherjee
Grab these four top stocks that have shown tremendous promise despite market volatility due to the pandemic and have the potential to continue their bull run in 2021.
Abbott's (ABT) Libre 2 Cleared in Canada, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) next-generation FreeStyle Libre 2 system aims to provide a better quality of life to diabetics in Canada at the same affordable price of the current FreeStyle Libre system.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $107.53, marking a -0.57% move from the previous day.
4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success
by Debanjana Dey
Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.
Pediatric Medical Space Thrives Amid COVID-19: 3 Stocks in Focus
by Zacks Equity Research
Among several domains within the MedTech space, several pediatric medical device stocks have been gaining traction amid the coronavirus pandemic